AmpliChip CYP450 Test
The FDA recently cleared the AmpliChip CYP450 Test (Roche), which analyzes blood-derived DNA to detect genetic variations in the activity of cytochrome P450 (CYP) enzymes CYP2D6 and CYP2C19 and determines the metabolizer status of the patient. The test is intended to help guide clinicians in prescribing individualized drug therapy. About 25% of all drugs, including many antidepressants and antipsychotics, are substrates of either CYP2D6 or CYP2C19. The test is being promoted initially to psychiatrists....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: AmpliChip CYP450 Test
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1215
Article Code: 1215e
Date: August 15, 2005
Volume: 47
Pages: 71-72
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1215
Article Code: 1215e
Date: August 15, 2005
Volume: 47
Pages: 71-72
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)